Market Cap 95.36B
Revenue (ttm) 48.30B
Net Income (ttm) -8.95B
EPS (ttm) N/A
PE Ratio 6.61
Forward PE 7.29
Profit Margin -18.53%
Debt to Equity Ratio 2.85
Volume 14,877,240
Avg Vol 14,497,216
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 48%
Beta 0.36
Analysts Sell
Price Target $56.05

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
MF__DOOM
MF__DOOM Jul. 15 at 9:29 PM
0 · Reply
theoptionsplug
theoptionsplug Jul. 15 at 6:13 PM
$BMY if price can break and hold its 50 DMA it can take another stab at breaking out of this wedge to the upside 📈 Really clean setup.
0 · Reply
gargoyl
gargoyl Jul. 15 at 5:23 PM
$BLRX 👀 averaging in again .. - in an uptrend for past 3 months. - since April 7th low of 2.30, now 4.70 - high point was 7.77 on May 30th - that day she did 30m volume - her channel is about .80 cents wide from $5.06 ceiling pivot to $4 lower support currently - average lately volume is 50k - the pipeline w/ PDAC, collaborations & Gloria and Arymid partners are the risk reward hear 👂, the low expenses are Phil’s ace in hole as is cash on hand , roughly 20M to mid 2026 Target 🎯 $12 this year , $24 after $BMY $REGN $SNY Who’s longest the 🦋
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Jul. 15 at 3:21 PM
$BMY picked up some shares
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Jul. 15 at 2:31 PM
$PFE $AZN $BMY $MRNA $LLY - Lovely day to own Pharma, innit?
1 · Reply
myman1956
myman1956 Jul. 14 at 7:53 PM
$PFE $BMY $GSK Pfizer announce .43 dividend with last upgrade to $30.00 looks like a buy signal on a chart with news on Fidelity rating is up to 9.2 is strong buy. That has more approval drugs that is why profits of .92 last earnings was a .26 beat that raise the outlook. More people are taking medications each day must take once in the morning to take 3 times a day that plenty of reasons why $PFE will beat earnings is why the upgrade to $30.00.The company could rebound back to $35.00 to $40.00 by the end of this year with all of the drug approvals.
1 · Reply
gargoyl
gargoyl Jul. 14 at 2:48 PM
$BLRX 👀 pay attention here , it’s not if it’s when .. MM is playing red light green light 1-2-3 trying to inch up when you are not looking.. the wide bid ask and low volume can’t hide his book is at a breaking point up 👆 📈 $REGN $BMY $SNY Long the 🦋
0 · Reply
trade_goats
trade_goats Jul. 14 at 2:43 PM
0 · Reply
Sunny3999
Sunny3999 Jul. 14 at 2:36 PM
$PMN Finally it’s showing up ⬆️ $ABBV $BMY $MRK $PMN $SNY
0 · Reply
Fingerlickengood
Fingerlickengood Jul. 13 at 8:16 PM
$CDXS $BMY https://www2.codexis.com/bmsposter
2 · Reply
Latest News on BMY
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Jul 14, 2025, 1:52 PM EDT - 1 day ago

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?


2 Wonderful Dividends At Bargain Basement Prices

Jul 7, 2025, 11:45 AM EDT - 8 days ago

2 Wonderful Dividends At Bargain Basement Prices

REXR


New vaccine panel meeting underway

Jun 26, 2025, 11:46 AM EDT - 19 days ago

New vaccine panel meeting underway

BDX MRK UNH ZBH


I'm Buying Dividend Giants At Huge Discounts

Jun 20, 2025, 9:00 AM EDT - 25 days ago

I'm Buying Dividend Giants At Huge Discounts

ABBV CVX OXY PFE SHEL SLB TTE


Bristol Myers Squibb Announces Dividend

Jun 17, 2025, 4:16 PM EDT - 4 weeks ago

Bristol Myers Squibb Announces Dividend


BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

Jun 2, 2025, 7:42 AM EDT - 6 weeks ago

BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

BNTX


Avoid These Dividend Disasters Before It's Too Late

May 23, 2025, 8:15 AM EDT - 7 weeks ago

Avoid These Dividend Disasters Before It's Too Late

AMGN COP CVS CVX DLR GNL HD


Buy These 2 Beaten Down Stocks Now Before They Rally

May 19, 2025, 1:00 PM EDT - 2 months ago

Buy These 2 Beaten Down Stocks Now Before They Rally

AAT ARE PFE


5 Dirt-Cheap Dividends Paying Up To 7.6%

May 18, 2025, 8:35 AM EDT - 2 months ago

5 Dirt-Cheap Dividends Paying Up To 7.6%

AES AESI DINO PII


Final Trade: RIO, FCX, X, BMY

May 15, 2025, 6:27 PM EDT - 2 months ago

Final Trade: RIO, FCX, X, BMY

FCX RIO X


MF__DOOM
MF__DOOM Jul. 15 at 9:29 PM
0 · Reply
theoptionsplug
theoptionsplug Jul. 15 at 6:13 PM
$BMY if price can break and hold its 50 DMA it can take another stab at breaking out of this wedge to the upside 📈 Really clean setup.
0 · Reply
gargoyl
gargoyl Jul. 15 at 5:23 PM
$BLRX 👀 averaging in again .. - in an uptrend for past 3 months. - since April 7th low of 2.30, now 4.70 - high point was 7.77 on May 30th - that day she did 30m volume - her channel is about .80 cents wide from $5.06 ceiling pivot to $4 lower support currently - average lately volume is 50k - the pipeline w/ PDAC, collaborations & Gloria and Arymid partners are the risk reward hear 👂, the low expenses are Phil’s ace in hole as is cash on hand , roughly 20M to mid 2026 Target 🎯 $12 this year , $24 after $BMY $REGN $SNY Who’s longest the 🦋
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Jul. 15 at 3:21 PM
$BMY picked up some shares
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Jul. 15 at 2:31 PM
$PFE $AZN $BMY $MRNA $LLY - Lovely day to own Pharma, innit?
1 · Reply
myman1956
myman1956 Jul. 14 at 7:53 PM
$PFE $BMY $GSK Pfizer announce .43 dividend with last upgrade to $30.00 looks like a buy signal on a chart with news on Fidelity rating is up to 9.2 is strong buy. That has more approval drugs that is why profits of .92 last earnings was a .26 beat that raise the outlook. More people are taking medications each day must take once in the morning to take 3 times a day that plenty of reasons why $PFE will beat earnings is why the upgrade to $30.00.The company could rebound back to $35.00 to $40.00 by the end of this year with all of the drug approvals.
1 · Reply
gargoyl
gargoyl Jul. 14 at 2:48 PM
$BLRX 👀 pay attention here , it’s not if it’s when .. MM is playing red light green light 1-2-3 trying to inch up when you are not looking.. the wide bid ask and low volume can’t hide his book is at a breaking point up 👆 📈 $REGN $BMY $SNY Long the 🦋
0 · Reply
trade_goats
trade_goats Jul. 14 at 2:43 PM
0 · Reply
Sunny3999
Sunny3999 Jul. 14 at 2:36 PM
$PMN Finally it’s showing up ⬆️ $ABBV $BMY $MRK $PMN $SNY
0 · Reply
Fingerlickengood
Fingerlickengood Jul. 13 at 8:16 PM
$CDXS $BMY https://www2.codexis.com/bmsposter
2 · Reply
BuyNHold4riches
BuyNHold4riches Jul. 12 at 11:09 PM
$REPL is this a buyout candidate from $BMY ?
0 · Reply
Jleon1793
Jleon1793 Jul. 11 at 9:26 PM
$BMY Phewww my 47 CCs made it this week. One last touch in the 46.60s IMO before we start building support around 48
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Jul. 11 at 6:09 PM
$BMY NO growth … Value trap
0 · Reply
ZacksResearch
ZacksResearch Jul. 11 at 5:03 PM
$ABBV vs. $BMY: Why AbbVie Takes the Edge Right Now! 💪 Despite Humira sales decline, AbbVie's diverse portfolio with Skyrizi, Rinvoq, and new approvals like Vyalev positions it for solid long-term growth. Meanwhile, BMY faces near-term generic headwinds despite promising drug approvals. 🤔 See what makes the investment case strong for AbbVie 👉 https://www.zacks.com/stock/news/2573739/abbv-or-bmy-which-biopharma-giant-has-better-prospects-for-now?cid=sm-stocktwits-2-2573739-body-1310&ADID=SYND_STOCKTWITS_TWEET_2_2573739_BODY_1310
0 · Reply
Quantumup
Quantumup Jul. 11 at 3:03 PM
Goldman Sachs, on 7/10,🏁 $NBIX Buy-$182. $CRNX $TAK $BMY Goldman Sachs said in its initiation report:
0 · Reply
OnTheBalance
OnTheBalance Jul. 11 at 2:56 PM
$SLS this point is an important one regarding GPS therapy and tilts it towards ABBV and BMY. What are people's take on SLS009 and its various applications? Which firms? And what are the MRK connection points? And are there key connections because of AndersonMD and MSK? $ABBV $BMY own Ven and Aza, BAT for Control Arm patients, and Know Precisely how their drugs Perform.
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jul. 11 at 2:40 PM
$SLS important to Note: this Nice little run, happened, SINCE the Independent Data Monitoring Committee UNBLINDED Actual Phase 3 Overall Survival and Immune Response Data. - Actual Unblinded Phase 3 Data that Confirms GPs is Doing what it's done in 7 all Previous trials - Prevent Relapse and Extend Survival, including 2 AML Phase 2 CR trials. - $ABBV $BMY own Ven and Aza, BAT for Control Arm patients, and Know Precisely how their drugs Perform. -- Link to Trial Data Showing OS of 8 months for AML Cr2 Patients, on Aza Ven - BAT for control - its 8 months, just like the 3 Dr's treating actual patients have stated. Control arm Os is 8 months. Unblinded Phase 3 data: All pooled P3 patients, Control (Aza Ven) + Gps patients had a NOT YET MET OS > Greater than 13.5 months at Interim. Simple Math: Gps P3 patient mOS is a Not yet Met, Greater than > 19 months, in line with the Statistically Significant P2 results - 21 months. > 19 at a median Follow Up of 13.5 months https://www.reddit.com/r/sellaslifesciences/comments/1i8htb7/book_it_its_a_done_deal_gps_is_100_for_sure/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button
0 · Reply
Jleon1793
Jleon1793 Jul. 11 at 2:16 PM
$BMY Going to test 46.60s again?
0 · Reply
taxplanr
taxplanr Jul. 11 at 1:10 PM
$BNTX $MRNA $CVAC $BMY there is no future for malignantRNA in medicine
1 · Reply
ZacksResearch
ZacksResearch Jul. 11 at 1:03 PM
$ABBV or $BMY — which one’s the better bet right now? AbbVie’s got the edge as Skyrizi and Rinvoq growth continues to outpace Humira’s decline and broader portfolio headwinds. See what makes the investment case stronger for ABBV 👉 https://www.zacks.com/stock/news/2573739/abbv-or-bmy-which-biopharma-giant-has-better-prospects-for-now?cid=sm-stocktwits-0-2573739-teaser-1309&ADID=SYND_STOCKTWITS_TWEET_0_2573739_TEASER_1309
0 · Reply
framus_morrigan
framus_morrigan Jul. 11 at 10:06 AM
$BMY Potential iHS pattern in the making. Weekly chart
0 · Reply
gargoyl
gargoyl Jul. 11 at 2:56 AM
$BLRX 👀 2 of 4 Something big is brewing.. tomorrow pop 💥 $BMY watch peeps 🐥
0 · Reply